<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295486</url>
  </required_header>
  <id_info>
    <org_study_id>20190973</org_study_id>
    <nct_id>NCT04295486</nct_id>
  </id_info>
  <brief_title>Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty</brief_title>
  <official_title>Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is attempting to answer the question of whether 81 mg aspirin once daily
      is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint
      replacement surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of symptomatic thromboembolic events</measure>
    <time_frame>90 days</time_frame>
    <description>Efficacy of prophylaxis will be reported as the number of reported incidence of symptomatic Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of specific adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Efficacy of prophylaxis will be reported as the number of reported incidence of specific adverse events including gastrointestinal (GI) complications, post-operative hematoma, bleeding and wound complications and infections.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5478</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Treatment Once Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant receives 81 mg aspirin taken once daily beginning the night before surgery and up to 28 days post surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Twice Daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant receives 81 mg aspirin taken twice daily (one in the morning and one at night) beginning at the night before surgery and up to 28 days post surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Non-enteric coated 81 mg Aspirin tablet.</description>
    <arm_group_label>Treatment Once Daily</arm_group_label>
    <arm_group_label>Treatment Twice Daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  &gt; 18 years of age

          -  Planning to undergo a primary total hip or knee arthroplasty

        Exclusion Criteria:

          -  High risk patients for VTE as defined by:

               -  History of venous thromboembolism

               -  Active malignancy

               -  Known pro thrombotic condition

          -  BMI &gt; 40

          -  Patients requiring anticoagulation for pre-existing conditions

          -  Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory
             drugs for reasons such as peptic ulcer disease, intolerance, others.

          -  Patients not fluent in the language of the informed consent form

          -  Prisoners

          -  Pregnancy

          -  Reported to have mental illness or belonging to a vulnerable population
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramakanth Yakkanti, MD</last_name>
    <phone>502-689-3127</phone>
    <email>ramakanth.yakkanti@jhsmiami.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ramakanth Yakkanti</last_name>
      <phone>502-689-3127</phone>
      <email>ramakanth.yakkanti1@jhsmiami.org</email>
    </contact>
    <investigator>
      <last_name>Victor Hernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Victor Hugo Hernandez</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Chemoprophylaxis</keyword>
  <keyword>Hip Surgery</keyword>
  <keyword>Knee Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

